SEQUENT SCIENTIFIC SHARE PRICE

Sequent Scientific Ltd. is a leading manufacturer and exporter of specialized quality formulations aimed at fulfilling the diverse demands of the pharmaceutical industry. It manufactures formulations belonging to the anthelmintic and anti-parasitic segments. It was incorporated in 1985 with its headquarters in Mumbai. During FY 2021-2022, the company’s total revenue was Rs 1,423.66 crore, up 3.92% from the previous financial year, 2020-2021. On 29 August 2022, its market capitalization stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sequentscientific/PID01" 2,788 crore.  

Sequent Scientific Ltd.’s shares are listed on the Bombay Stock Exchange with the code 512529, and on the National Stock Exchange with the code SEQUENT.  

Sequent Scientific Ltd. is amongst the top 20 global animal health companies. It is backed by The Carlyle Group, a global investment firm. The company has eight manufacturing facilities across Turkey, Europe, Brazil, and India. The Vizag site in India is the country’s only USFDA-approved dedicated veterinary API facility.  

The company’s shareholding pattern at the end of the June 2022 quarter showed a promoter stake of 52.79%, foreign institutional investor stake of 6.45%, domestic institutional investor stake of 2.26%, and public stake of 38.1%. The entire promoter share belongs to CA Harbor Investments. During the June 2022 quarter, promoter holdings decreased from 53.02% to 52.79%, mutual fund holdings reduced from 0.30% to 0.29%, and FII holdings increased from 5.84% to 6.45%.  

Mr Manish Gupta is the company’s managing director and CEO. Its board members include Dr Kamal K Sharma, Mr Sharat Narasapur, Mr Neeraj Bharadwaj, Mr Rahul Mukim, Dr Fabian Kausche, Mr Gregory John Andrews, and Dr (Mrs) Kausalya Santhanam. The auditors of the company are S R B C & Co. LLP. On 30 June 2022, the company had a total of 24.94 crore shares outstanding.  

On 29 August 2022, the company’s share price closed at Rs 112.50 on BSE and at Rs 111.80 on NSE. The 52-week high for Sequent Scientific Ltd.’s share price was Rs 239.70, and the 52-week low for the company’s share price was Rs 82.  

The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd.  

As of August 2022, White Oak Capital Flexi Cap Fund had a 0.45% stake in Sequent Scientific Ltd. 

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose 

Sequent Scientific Ltd. is a leading manufacturer and exporter of specialized quality formulations aimed at fulfilling the diverse demands of the pharmaceutical industry. It manufactures formulations belonging to the anthelmintic and anti-parasitic segments. It was incorporated in 1985 with its headquarters in Mumbai. During FY 2021-2022, the company’s total revenue was Rs 1,423.66 crore, up 3.92% from the previous financial year, 2020-2021. On 29 August 2022, its market capitalization stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sequentscientific/PID01" 2,788 crore.  

Sequent Scientific Ltd.’s shares are listed on the Bombay Stock Exchange with the code 512529, and on the National Stock Exchange with the code SEQUENT.  

Sequent Scientific Ltd. is amongst the top 20 global animal health companies. It is backed by The Carlyle Group, a global investment firm. The company has eight manufacturing facilities across Turkey, Europe, Brazil, and India. The Vizag site in India is the country’s only USFDA-approved dedicated veterinary API facility.  

The company’s shareholding pattern at the end of the June 2022 quarter showed a promoter stake of 52.79%, foreign institutional investor stake of 6.45%, domestic institutional investor stake of 2.26%, and public stake of 38.1%. The entire promoter share belongs to CA Harbor Investments. During the June 2022 quarter, promoter holdings decreased from 53.02% to 52.79%, mutual fund holdings reduced from 0.30% to 0.29%, and FII holdings increased from 5.84% to 6.45%.  

Mr Manish Gupta is the company’s managing director and CEO. Its board members include Dr Kamal K Sharma, Mr Sharat Narasapur, Mr Neeraj Bharadwaj, Mr Rahul Mukim, Dr Fabian Kausche, Mr Gregory John Andrews, and Dr (Mrs) Kausalya Santhanam. The auditors of the company are S R B C & Co. LLP. On 30 June 2022, the company had a total of 24.94 crore shares outstanding.  

On 29 August 2022, the company’s share price closed at Rs 112.50 on BSE and at Rs 111.80 on NSE. The 52-week high for Sequent Scientific Ltd.’s share price was Rs 239.70, and the 52-week low for the company’s share price was Rs 82.  

The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd.  

As of August 2022, White Oak Capital Flexi Cap Fund had a 0.45% stake in Sequent Scientific Ltd. 

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose